Showing 5181-5190 of 9301 results for "".
- HydraFacial and Vesper Healthcare Announce Closing of Business Combination, Combined Company Now Known as The Beauty Health Companyhttps://practicaldermatology.com/news/hydrafacial-and-vesper-healthcare-announce-close-business-combination-combined-company-now-known-as-the-beauty-health-company/2460800/It's officially official: Vesper Healthcare and The HydraFacial Company closed their previously announced business combination. The combined company will be known as The Beauty Health Company. The business combination was approved by Vesper Healthcare’s st
- Arcutis to Present New Data for Roflumilast in PsO at EADVhttps://practicaldermatology.com/news/arcutis-to-present-new-data-for-roflumilast-in-pso-at-eadv/2460798/New data from the DERMIS-1 and DERMIS-2 pivotal phase 3 studies evaluating roflumilast cream (ARQ-151) show that the investigational once daily, topical PDE4 inhibitor for psoriasis achieved the primary efficacy endpoint of IGA success at week eight for chronic plaque psoriasis. Data are being pr
- Mederma Survey: America's Got Skin Insecuritieshttps://practicaldermatology.com/news/mederma-survey-skin-insecurities-have-major-impact-on-mental-health/2460797/One-third of Americans would not use their smart phone for a year if it meant they could have picture-perfect skin, according to a new survey from Mederma. That’s not all they would do for clear skin either, many would cancel Netflix for life eat only oatmeal for a year, giv
- FDA Accepts Amgen's sNDA for Otezla in Mild-to-Moderate PsOhttps://practicaldermatology.com/news/fda-accepts-amgens-snda-for-otezla-in-mild-to-moderate-pso/2460796/FDA has accepted for review the supplemental New Drug Application (sNDA) for Amgen's Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA has set a PDUFA action date of
- CorEvitas Enrolls 15,000 Patients in its Psoriasis and AD Registrieshttps://practicaldermatology.com/news/corevitas-enrolls-15000-patients-in-its-psoriasis-and-ad-registries/2460795/CorEvitas has enrolled more than 15,000 patients with immune-mediated skin diseases in the CorEvitas registries for moderate to severe psoriasis and atopic dermatitis (AD). This milestone was achieved by building on the company's real-world evidence program and dermatolog
- DermTech Launches New Campaign to Bring Awareness to Need for Skin Cancer Skin Examshttps://practicaldermatology.com/news/dermtech-launches-new-campaign-to-bring-awareness-to-need-for-skin-cancer-skin-exams/2460793/To honor May as Melanoma and Skin Cancer Awareness Month,
- Breaking Business News: Cynosure to Acquire MyEllevate Surgical Suture Systemhttps://practicaldermatology.com/news/breaking-business-news-cynosure-to-acquire-myellevate-surgical-suture-system/2460791/Cynosure is acquiring the MyEllevate Surgical Suture System, which allows practitioners to place a suture support system without incisions. MyEllevate, performed with the ICLED light-guided suture system, is the first and only patented light-guided technology for use in soft tissue
- AAD Survey: One-Third of Americans Flunk Basic Quiz on Skin Cancer and Sun Exposurehttps://practicaldermatology.com/news/aad-survey-one-third-of-americans-flunk-basic-quiz-on-skin-cancer-and-sun-exposure/2460785/One-third of Americans lack a basic understanding of skin cancer and sun protection, according to a recent survey of 1,000 U.S. adults from the American Academy of Dermatology. Shockingly, more than half (53%) of adults are unaware that shade can protect them from the sun’s harmfu
- Daily Avena Sativa Skincare Regimen Improves Itch and Dry Skin in Adults Undergoing Systemic Cancer Treatmentshttps://practicaldermatology.com/news/daily-avena-sativa-skincare-regimen-improves-itch-and-dry-skin-in-adults-undergoing-systemic-cancer-treatments-1/2460780/Daily Avena Sativa (Oat) skincare regimen provides a significant improvement in xerosis and pruritus for adult patients undergoing systemic oncology treatments,according to research presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021. "The u
- Accure Acne Seeks to Raise Up To $20 Million Through Private Placement Offeringhttps://practicaldermatology.com/news/accure-acne-seeks-to-raise-up-to-20-million-through-private-placement-offering/2460776/Accure Acne, Inc. has launched a private placement offering on the M-Vest platform to raise up to $20 Million. Building on the research of R. Rox Anderson, MD, Accure Co-Founder and Chief Scientific & Medical Officer, Accure has developed the Accure Laser System, an&n